Results 81 to 90 of about 38,007 (143)

An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks. [PDF]

Invest New Drugs
Kondo S, Kitano S, Sato J, Katsuya Y, Kogawa T, Mizugaki H, Miyamoto I, Iwasawa S, Imaizumi T, Tomita H, Murakami C, Miyake T, Yamamoto N.   +12 more
europepmc   +1 more source

Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials. [PDF]

J Neurol
Zid Y, Robertson NP.
europepmc   +1 more source

Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience. [PDF]

Curr Neuropharmacol
Zanghì A, Ferraro D, Callari G, Valentino P, Granella F, Patti F, Lus G, Bonavita S, Moretti MC, Avolio C, D'Amico E.   +10 more
europepmc   +1 more source

Clinical outcomes in OPAT patients treated with ceftriaxone 4 g and ceftazidime 6 g extended interval dosing regimens. [PDF]

JAC Antimicrob Resist
Wareham D, Melzer M.
europepmc   +1 more source

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system. [PDF]

Lancet Oncol
Bryant AK, Lewy JR, Bressler RD, Chopra Z, Gyori DJ, Bazzell BG, Moeller JA, Jacobson SI, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Vaishnav P, Strohbehn GW.   +14 more
europepmc   +1 more source

Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis. [PDF]

Mult Scler
Toorop AA, Noteboom S, Steenwijk MD, Gravendeel JW, Jasperse B, Barkhof F, Strijbis EM, Rispens T, Schoonheim MM, van Kempen ZL, Killestein J.   +10 more
europepmc   +1 more source

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients. [PDF]

J Neurol
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A, OCREVID study group on behalf of the Italian MS Register.   +15 more
europepmc   +1 more source

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. [PDF]

Mult Scler Relat Disord, 2020
Borriello G, Ianniello A.
europepmc   +1 more source

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2020
Rempe T, Wang Q, Wu Q, Ballur Narayana Reddy V, Newcomer Z, Miravalle A, Mao-Draayer Y.   +6 more
europepmc   +1 more source

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus. [PDF]

Antimicrob Agents Chemother, 2019
Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Wickes BL, Catano G, Patterson TF.   +6 more
europepmc   +1 more source